These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 23025349)

  • 1. Validated in vitro/in vivo correlation of prolonged-release oxycodone/naloxone with differing dissolution rates in relation to gastrointestinal transit times.
    Mundin GE; Smith KJ; Mysicka J; Heun G; Krämer M; Hahn U; Leuner C
    Expert Opin Drug Metab Toxicol; 2012 Dec; 8(12):1495-503. PubMed ID: 23025349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.
    Smith K; Hopp M; Mundin G; Leyendecker P; Bailey P; Grothe B; Uhl R; Reimer K
    Clin Ther; 2008 Nov; 30(11):2051-68. PubMed ID: 19108793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers.
    Smith K; Hopp M; Mundin G; Bond S; Bailey P; Woodward J; Palaniappan K; Church A; Limb M; Connor A
    Expert Opin Investig Drugs; 2011 Apr; 20(4):427-39. PubMed ID: 21395483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of prolonged-release oxycodone/naloxone on pain control, bowel function and quality of life: A prospective observational study.
    Hesselbarth S; Löwenstein O; Cegla T
    Scand J Pain; 2014 Apr; 5(2):75-81. PubMed ID: 29913668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers.
    Kapil R; Nolting A; Roy P; Fiske W; Benedek I; Abramowitz W
    Clin Ther; 2004 Dec; 26(12):2015-25. PubMed ID: 15823765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro-in vivo correlation for nevirapine extended release tablets.
    Macha S; Yong CL; Darrington T; Davis MS; MacGregor TR; Castles M; Krill SL
    Biopharm Drug Dispos; 2009 Dec; 30(9):542-50. PubMed ID: 19876936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ENhANCE trial protocol: A multi-centre, randomised, phase IV trial comparing the efficacy of oxycodone/naloxone prolonged release (OXN PR) versus oxycodone prolonged release (Oxy PR) tablets in patients with advanced cancer.
    Wong AK; Grobler A; Le B
    Contemp Clin Trials Commun; 2022 Dec; 30():101036. PubMed ID: 36407843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx®: an extended-release, abuse-deterrent formulation.
    Kopecky EA; Fleming AB; Noonan PK; Varanasi RK; Grima M; Saim S; Mayock SP
    J Opioid Manag; 2014; 10(4):233-46. PubMed ID: 25162603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro and in-vivo correlation for two gliclazide extended-release tablets.
    Mandal U; Ray KK; Gowda V; Ghosh A; Pal TK
    J Pharm Pharmacol; 2007 Jul; 59(7):971-6. PubMed ID: 17637192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined oral prolonged-release oxycodone and naloxone in chronic pain management.
    Mercadante S; Giarratano A
    Expert Opin Investig Drugs; 2013 Jan; 22(1):161-6. PubMed ID: 23215628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
    Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
    Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorption.
    Willmann S; Edginton AN; Kleine-Besten M; Jantratid E; Thelen K; Dressman JB
    J Pharm Pharmacol; 2009 Jul; 61(7):891-9. PubMed ID: 19589231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation.
    Kovacević I; Parojcić J; Homsek I; Tubić-Grozdanis M; Langguth P
    Mol Pharm; 2009; 6(1):40-7. PubMed ID: 19248231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-a-day extended-release dosage form of divalproex sodium III: development and validation of a Level A in vitro-in vivo correlation (IVIVC).
    Dutta S; Qiu Y; Samara E; Cao G; Granneman GR
    J Pharm Sci; 2005 Sep; 94(9):1949-56. PubMed ID: 16052544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro/in vivo correlations of dissolution data of carbamazepine immediate release tablets with pharmacokinetic data obtained in healthy volunteers.
    Lake OA; Olling M; Barends DM
    Eur J Pharm Biopharm; 1999 Jul; 48(1):13-9. PubMed ID: 10477323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irregular absorption profiles observed from diclofenac extended release tablets can be predicted using a dissolution test apparatus that mimics in vivo physical stresses.
    Garbacz G; Wedemeyer RS; Nagel S; Giessmann T; Mönnikes H; Wilson CG; Siegmund W; Weitschies W
    Eur J Pharm Biopharm; 2008 Oct; 70(2):421-8. PubMed ID: 18582568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation.
    Meissner W; Leyendecker P; Mueller-Lissner S; Nadstawek J; Hopp M; Ruckes C; Wirz S; Fleischer W; Reimer K
    Eur J Pain; 2009 Jan; 13(1):56-64. PubMed ID: 18762438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and in vivo evaluation of oxycodone once-a-day controlled-release tablets.
    Kim JY; Lee SH; Park CW; Rhee YS; Kim DW; Park J; Lee M; Seo JW; Park ES
    Drug Des Devel Ther; 2015; 9():695-706. PubMed ID: 25678774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population In Vitro-In Vivo Correlation Model Linking Gastrointestinal Transit Time, pH, and Pharmacokinetics: Itraconazole as a Model Drug.
    Abuhelwa AY; Mudge S; Hayes D; Upton RN; Foster DJ
    Pharm Res; 2016 Jul; 33(7):1782-94. PubMed ID: 27119846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.